News Focus
News Focus
icon url

dennisdave

03/14/25 4:05 PM

#754226 RE: exwannabe #754217

I suspect though that Iron and various other rational longs (a disjoint subset from the longs who think the Earth revolves around NWBO) get tired of them making NWBO look like a cult stock for drunk college kids.

One NWBO cult member post makes me want to sell all my NWBO shares at a loss faster than 1000 Exwannebe posts will ever be able to do. Go figure.
icon url

SkyLimit2022

03/16/25 7:28 PM

#754476 RE: exwannabe #754217

ex,

You love 💕 our dot connecting! 😉

And the recent green light for the expansion of the pembrolizumab combo research has brought some focus back on the
Merck dot connecting too!

Grant-funded trials are
peer-reviewed, and the reviewers generally approve funding/expansion based on preliminary data. Notably, the PII trials at Roswell Park have been approved to expand in scope.. and look who joked on X about the overly-rigorous peer-review process for grant funding—the principal investigator of one of the Roswell trials!

So, it looks like the grant peer reviewers have been watching the PII trials closely 🤔 …

Since the peer-reviewed Roswell trials include pembrolizumab, we are a bit curious about
Merck’s interest and awareness of DC platforms and how emerging interim data might lead to new combo possibilities…

These three scientists have coauthored several publications on
dendritic cell vaccines, and all three were recently recruited by Merck in 2023 and 2024:
☑️ Juraj Adamik
☑️ Paul Munson
☑️ Lisa H. Butterfield


https://acir.org/weekly-digests/2023/november/metabolic-characteristics-of-dc-vaccines-define-therapy-responses

https://www.nature.com/articles/s41467-023-42881-4

https://www.nature.com/articles/s41467-022-32849-1




https://www.sciencedirect.com/science/article/abs/pii/B9780128239018000030

Adamik and Butterfield are coauthors of this publication along with several University of Pittsburgh researchers:
https://rupress.org/jem/article/217/7/e20191369/151736/Impact-of-checkpoint-blockade-on-cancer-vaccine

Pawel Kalinski of Roswell Park and Lisa Butterfield are coauthors on this 2021 publication:
https://jitc.bmj.com/content/9/11/e003675

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175085456

Roswell DC Platform:


In addition to the expansion referenced above in a recent NWBO SEC filing, the other PII also had a recent change…

⭐️ Trial Update Published 27 Feb 2025:

https://clinicaltrials.gov/study/NCT04348747?a=29&b=30

The trial scope and title were expanded to include hormone receptor-positive (HR+) breast cancer, the most common subtype.

☑️ Increased Patient Eligibility: A broader population now qualifies.

☑️ Scientific Implications: Potential efficacy beyond TNBC and HER2+ cases, possibly due to shared immune mechanisms.

☑️ Regulatory & Market Impact: Broader applicability could enhance approval prospects and market potential.

☑️ Trial Design Adjustments: May involve new stratification to account for differences in tumor biology.

Dr. Kabraji recently mentioned and cited the pembrolizumab + DC vaccine trial in a passing comment on X in response to someone on another topic, but I found his comment insightful considering the date of his X reply post and the context of the recent trial updates…his post was just weeks before he became the principal investigator of that trial…

Bullish
Bullish
icon url

Perk_Idaho

03/16/25 8:32 PM

#754485 RE: exwannabe #754217

I find your presense her humorous. Saving everyone from themselves, yet.... most longs are very likely (100% confident that I am) financially secure beyond your means/wildest imagination. But thanks for your concern. Hey, St. Patty's day tomorrow, gotta run, hostin 20 of my closest friends, gotta prep 4 waygu corned beef's. Cheers fellas.